Zawitz David 4
4 · Verrica Pharmaceuticals Inc. · Filed Nov 25, 2025
Insider Transaction Report
Form 4
Zawitz David
Chief Operating Officer
Transactions
- Purchase
Series C Warrant (right to buy)
2025-11-25+2,500→ 2,500 totalExercise: $6.32Exp: 2030-11-25→ Common Stock (2,500 underlying) - Purchase
Common Stock
2025-11-25$4.24/sh+10,000$42,425→ 21,000 total
Footnotes (3)
- [F1]Effective July 24, 2025, the Issuer effected a 1-for-10 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split.
- [F2]Immediately exercisable.
- [F3]The reported securities are included within 10,000 investment units purchased by the Reporting Person for $4.2425 per investment unit. Each investment unit consists of one share of Common Stock and a Series C warrant for one fourth of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series C Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise.